Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study.
Journal
European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966
Informations de publication
Date de publication:
09 Dec 2023
09 Dec 2023
Historique:
pubmed:
26
8
2023
medline:
26
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Missed opportunities constitute a main driver of suboptimal seasonal influenza vaccination (SIV) coverage in older adults. Vaccine co-administration is a way to reduce these missed opportunities. In this study, we quantified missed opportunities for SIV, identified some of their socio-structural correlates and documented SIV co-administration patterns. In this registry-based retrospective cohort study, we verified the SIV status of all subjects aged ≥65 years who received at least one dose of coronavirus disease 2019 (COVID-19), pneumococcal or herpes zoster vaccines during the 2022/23 influenza season. The frequency of concomitant same-day administration of SIV with other target vaccines was also assessed. Among 41 112, 5482 and 3432 older adults who received ≥1 dose of COVID-19, pneumococcal and herpes zoster vaccines, missed opportunities for SIV accounted for 23.3%, 5.0% and 13.2%, respectively. Younger, male and foreign-born individuals were generally more prone to missing SIV. The co-administration of SIV with other recommended vaccines was relatively low, being 11.0%, 53.1% and 17.1% in COVID-19, pneumococcal and herpes zoster cohorts, respectively. A sizeable proportion of older adults who received other recommended vaccines during the last influenza season did not receive SIV. This share of missed opportunities, which are subject to some social inequalities, may be addressed by increasing vaccine co-administration rates and implementing tailored health promotion interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Missed opportunities constitute a main driver of suboptimal seasonal influenza vaccination (SIV) coverage in older adults. Vaccine co-administration is a way to reduce these missed opportunities. In this study, we quantified missed opportunities for SIV, identified some of their socio-structural correlates and documented SIV co-administration patterns.
METHODS
METHODS
In this registry-based retrospective cohort study, we verified the SIV status of all subjects aged ≥65 years who received at least one dose of coronavirus disease 2019 (COVID-19), pneumococcal or herpes zoster vaccines during the 2022/23 influenza season. The frequency of concomitant same-day administration of SIV with other target vaccines was also assessed.
RESULTS
RESULTS
Among 41 112, 5482 and 3432 older adults who received ≥1 dose of COVID-19, pneumococcal and herpes zoster vaccines, missed opportunities for SIV accounted for 23.3%, 5.0% and 13.2%, respectively. Younger, male and foreign-born individuals were generally more prone to missing SIV. The co-administration of SIV with other recommended vaccines was relatively low, being 11.0%, 53.1% and 17.1% in COVID-19, pneumococcal and herpes zoster cohorts, respectively.
CONCLUSIONS
CONCLUSIONS
A sizeable proportion of older adults who received other recommended vaccines during the last influenza season did not receive SIV. This share of missed opportunities, which are subject to some social inequalities, may be addressed by increasing vaccine co-administration rates and implementing tailored health promotion interventions.
Identifiants
pubmed: 37632235
pii: 7251525
doi: 10.1093/eurpub/ckad155
pmc: PMC10710345
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183-1187Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association.
Références
BMC Med. 2012 May 31;10:55
pubmed: 22651695
Lancet Respir Med. 2022 Apr;10(4):392-402
pubmed: 35114141
J Am Geriatr Soc. 2007 Oct;55(10):1499-507
pubmed: 17908055
J Prev Med Hyg. 2017 Dec 30;58(4):E279-E287
pubmed: 29707658
Am J Public Health. 2012 Apr;102(4):596-605
pubmed: 22397339
Lancet. 2021 Dec 18;398(10318):2277-2287
pubmed: 34774197
Vaccine. 2017 Jan 5;35(2):313-320
pubmed: 27919632
Vaccines (Basel). 2021 Sep 13;9(9):
pubmed: 34579253
Euro Surveill. 2018 Apr;23(16):
pubmed: 29692315
Vaccine. 2017 Nov 1;35(46):6321-6328
pubmed: 28987445
PLoS One. 2016 Nov 10;11(11):e0166517
pubmed: 27832186
Hum Vaccin Immunother. 2023 Dec 31;19(1):2195786
pubmed: 37039318
BMJ Open. 2016 Dec 21;6(12):e012812
pubmed: 28003289
Hum Vaccin Immunother. 2020 Jun 2;16(6):1313-1321
pubmed: 31810408
Vaccine. 2021 Jun 11;39(26):3520-3527
pubmed: 34023136
Prev Med. 2021 Sep;150:106694
pubmed: 34171345
Ann Intern Med. 2022 Jan;175(1):1-10
pubmed: 34781717
Vaccine. 2022 Jul 30;40(32):4380-4393
pubmed: 35781171
J Infect Dis. 2017 Dec 12;216(11):1352-1361
pubmed: 29029224
Arch Pediatr Adolesc Med. 2001 Mar;155(3):382-6
pubmed: 11231806
Pharmaceuticals (Basel). 2022 Mar 08;15(3):
pubmed: 35337120
Eur J Public Health. 2003 Jun;13(2):133-7
pubmed: 12803411
Immun Ageing. 2021 Oct 9;18(1):38
pubmed: 34627326
Vaccine. 2022 Mar 8;40(11):1643-1654
pubmed: 33933316
J Public Health Manag Pract. 1996 Winter;2(1):18-25
pubmed: 10186652
J Prim Care Community Health. 2015 Jul;6(3):147-53
pubmed: 25432588
Vaccine. 2023 Mar 24;41(13):2137-2146
pubmed: 36828719
BMC Public Health. 2013 Apr 25;13:388
pubmed: 23617788
Vaccine. 2018 Jan 25;36(4):442-452
pubmed: 29287683
Epidemiol Rev. 1999;21(1):96-142
pubmed: 10520476
Ann Med. 2023 Dec;55(1):2196436
pubmed: 37052255
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
J Am Board Fam Pract. 2005 Jan-Feb;18(1):20-7
pubmed: 15709060